Healthcare Industry News: acute myocardial infarction
News Release - May 3, 2006
Vasomedical Sells Its 1,000th EECP Therapy SystemSignificant Milestone Achieved with Sale to St. Francis Hospital, The Heart Center in Roslyn, NY
WESTBURY, N.Y.--(HSMN NewsFeed)--May 3, 2006--Vasomedical, Inc. (Nasdaq SC: VASO), a leader in the noninvasive treatment and management of cardiovascular diseases, announced today that the company has reached a significant milestone with the sale of its 1,000th EECP® therapy system to St. Francis Hospital, The Heart Center® in Roslyn, New York. Vasomedical has sold EECP therapy systems to over 650 EECP therapy providers in the U.S. and over 90 treatment centers outside the U.S. since its first commercial sale in 1995.
"St. Francis Hospital, The Heart Center continues to demonstrate its commitment to providing high-quality services to patients with cardiovascular disease by offering EECP therapy with Vasomedical's state-of-the-art Lumenair(TM) system," stated Dr. Justine Lachmann, director of the Congestive Heart Failure Program at St. Francis Hospital.
"Our entire organization is proud to have achieved this major milestone, especially when considering the tens of thousands of patients who have enjoyed the benefits of EECP therapy through the elimination or reduction of their angina symptoms and the subsequent improvement in their quality of life," said Thomas Glover, president and chief executive officer.
Vasomedical has designed, developed and introduced four generations of EECP therapy systems, the Model MC-2, Model TS3, Model TS4 and Lumenair and, has sponsored two positive randomized trials in addition to a 7,500 patient registry to help demonstrate the safety and efficacy of the therapy. The company markets and promotes EECP therapy systems as part of a total product offering that includes comprehensive clinical, technical, marketing and reimbursement support.
About St. Francis Hospital, The Heart Center®
St. Francis Hospital, The Heart Center is New York State's only specialty designated cardiac center and is one of the five busiest heart centers in the United States. St Francis is a recognized leader in the diagnosis, treatment and prevention of cardiac disease. St. Francis Hospital is a member of the Catholic Health Services of Long Island (CHS). The Heart Center is a trademark of St. Francis Hospital.
About EECP® Therapy
EECP external counterpulsation therapy is typically given in 35 one-hour sessions over seven weeks. Patients recline on a contoured treatment table and their calves, lower thighs and upper thighs are wrapped in a pneumatic cuff set. The system, which is synchronized to the individual patient's cardiac cycle, inflates the cuffs with air to create external pressure when the heart is resting and deflates the cuffs just before the next heartbeat. The system's action, which pulses counter to the heart's beating, increases blood flow to the heart muscle and other organs and decreases the heart's workload, creating a greater oxygen supply for the heart muscle while lowering its need for oxygen.
About Vasomedical, Inc.
Vasomedical, Inc. is primarily engaged in designing, manufacturing, marketing and supporting EECP external counterpulsation systems based on the Company's unique proprietary technology. EECP therapy is a noninvasive, outpatient therapy for the treatment of diseases of the cardiovascular system currently indicated for use in cases of stable or unstable angina, congestive heart failure, acute myocardial infarction and cardiogenic shock. The therapy serves to increase circulation in areas of the heart with less than adequate blood supply and may restore systemic vascular function. The Company provides hospitals, clinics and private practices with EECP equipment, treatment guidance and a staff training and equipment maintenance program designed to provide optimal patient outcomes. Additional information is available on the Company's website at www.vasomedical.com. EECP is a registered trademark for Vasomedical's enhanced external counterpulsation systems.
Except for historical information contained in this release, the matters discussed are forward-looking statements that involve risks and uncertainties. When used in this report, words such as "anticipated," "believes," "could," "estimates," "expects," "may," "plans," "potential" and "intends" and similar expressions, as they relate to the Company or its management, identify forward-looking statements. Such forward-looking statements are based on the beliefs of the Company's management, as well as assumptions made by and information currently available to the Company's management. Among the factors that could cause actual results to differ materially are the following: the effect of the dramatic changes taking place in the healthcare environment; the impact of competitive procedures and products and their pricing; medical insurance reimbursement policies; unexpected manufacturing or supplier problems; unforeseen difficulties and delays in product development programs; the actions of regulatory authorities and third-party payers in the United States and overseas; uncertainties about the acceptance of a novel therapeutic modality by the medical community; and the risk factors reported from time to time in the Company's SEC reports. The Company undertakes no obligation to update forward-looking statements as a result of future events or developments.
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.